Atrial fibrillation link to cancer drug highlights urgent need for guidelines

There is a “clear and pressing need” to improve the management of patients with chronic lymphocytic leukaemia who develop atrial fibrillation as a result of ibrutinib (Imbruvica) treatment, Sydney experts have claimed. Haematologists Professor Stephen Mulligan and Professor Christopher Ward, with electrophysiologist Dr David Whalley and pharmacologist Professor Sarah Hilmer, said it is essential to ...

Already a member?

Login to keep reading.

© 2021 the limbic